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Abstract Previous reports showed that human RAD50
(hRAD50) gene delivery induced regression of an experimental
rat tumor and porcine neointimal hyperplasia. In this study, we
examined the e¡ects of hRAD50 on the morphological changes
and migration of endothelial cells (EC) as possible mechanisms
by which hRAD50 might block angiogenesis. Quantitative im-
age analysis revealed signi¢cant inhibition of the number and
total area of blood vessels in rat tumor tissues following
hRAD50 gene delivery. hRAD50 distorted actin and tubulin
arrangements, and signi¢cantly reduced the F/G-actin ratio
and increased the nitric oxide (NO) production in the primary
cultured human EC. These e¡ects were blocked by pretreatment
with L-NAME (NG-nitro-L-arginine-methyl ester), a NO syn-
thase inhibitor. FACScan analysis showed that NO was involved
in the necrosis and apoptosis of EC by hRAD50. hRAD50 also
inhibited EC migration in an in vitro wound-healing model.
These results indicate that NO-dependent cytoskeletal changes
and inhibition of EC migration contribute to the suppression of
angiogenesis by hRAD50 delivery in vivo.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Human RAD50 (hRAD50) is a nuclear protein that exhib-
its a limited degree of homology to chromosomal structural
maintenance proteins and synaptonemal complex proteins [1],
and has limited epitopic homology to p53 [2]. hRAD50 is part
of a trimeric complex, hRAD50/MRE11/NBS1. This complex
functions in DNA damage detection and repair. The hRAD50
is an abundant protein that is uniformly distributed in the
nuclei of cultured cells. Following gamma irradiation, both
hRAD50 and hMRE11 formed discrete nuclear foci, which
are referred to as ionizing radiation-induced foci, indicating
that hRAD50 and hMRE11 exhibit a dynamic redistribution
within the nucleus after treatment with agents that induce
DNA double-strand break [3]. Recently, we observed that
hRAD50 overexpression in cultured non-endothelial cells
(non-EC) caused p21-caspase-dependent cell death [4]. We
also showed that overexpression of hRAD50 in several cul-
tured cells, such as HeLa and SaOS-2 cells, induced necrosis
and apoptosis. We observed inducible nitric oxide synthase
(iNOS) induction in the regressed tumor tissues when we in-
jected the hRAD50 gene into subcutaneous adenocarcinoma
in an experimental rat or mouse model. In vivo, hRAD50
gene delivery clearly had antitumor activity.
The mechanism of hRAD50’s antitumor activity is un-
known, but it appears to involve a reduction of angiogenesis
through the activity of NO as well as p21-caspase-dependent
direct cytotoxic action. In hRAD50-transfected tumor sec-
tions, there were fewer blood vessels than in the control sec-
tion. Also, hRAD50 gene transfer caused deaths of cultured
human coronary arterial EC (HCAEC) and human coronary
arterial smooth muscle cells (HCASMC) [5]. Compared with
non-EC, increased endothelial NO synthase (eNOS) expres-
sion as well as p21 expression was observed in the EC. NO
production was signi¢cantly increased in the hRAD50 group
compared with the vector group after transient transfection.
The Western result that iNOS was not induced by hRAD50
indicated that the increased NO generation was derived from
the eNOS activation by hRAD50. Pretreatment with NOS
and pan-caspase inhibitors completely prevented EC death
by hRAD50, indicating involvement of NO as well as caspase
in the profound EC death in the static culture model. We also
observed that local hRAD50 gene delivery could cause signi¢-
cant regression of preformed in-stent neointimal hyperplasia
in porcine coronary arteries without apparent systemic toxic-
ity [5].
The roles of NO in the cardiovascular system are complex
and include vessel relaxation, inhibition of the proliferation of
SMC and EC, and suppression of platelet adhesion [6]. The
eNOS protein is constitutively expressed in myocardial cells as
well as coronary EC, and has autocrine and paracrine actions
on cardiomyocytes and vascular cells [7]. Induction of apo-
ptosis by NO has been described in various cell lines [8,9],
while some studies have demonstrated that NO inhibits apo-
ptosis [10,11]. Thus, the role of NO in apoptosis appears to be
cell-type speci¢c. In EC, NO has both anti-apoptotic and pro-
apoptotic e¡ects depending on the NO concentration [12]. NO
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reacts rapidly with superoxide to form the highly toxic per-
oxynitrite, and it has been demonstrated that both NO and
peroxynitrite can damage DNA directly [13].
To investigate the possible mechanisms by which hRAD50
blocks angiogenesis, we studied the e¡ects of transient
hRAD50 gene transfer on the morphological phenotypes
and migration of primary cultured HCAEC. HCAEC were
chosen because it is di⁄cult to maintain stable hRAD50 over-
expression in primary cultured EC. Our present results suggest
that EC-speci¢c cytoskeletal changes and inhibition of EC
migration as well as profound NO- and caspase-mediated
EC death may be the underlying mechanisms that block an-
giogenesis and thereby cause regression of experimental tu-
mors and neointimal hyperplasia following hRAD50 delivery.
2. Materials and methods
2.1. Generation of experimental rat tumor model and
hRAD50 DNA injection into tumor
The rat tumor model was made by injecting 3U105 (50 Wl) RBA
cells subcutaneously in the right £anks of newborn (1V2 days)
Sprague^Dawley rats. The RBA cell was derived from rat mammary
adenocarcinoma (ATCC, CRL-1747). After 4 weeks, a palpable tu-
mor mass (diameter less than 1 cm) was con¢rmed and a gene ex-
pression cassette mixed with non-liposomal lipid FuGENE 6 (Boehr-
inger Mannheim) was injected directly into the tumor mass. Rats were
injected weekly, for 2 weeks, with a control pFLAG vector or
pFLAG-hRAD50 DNA, and survival of the animals was monitored
for 3V6 months following gene injection.
2.2. Morphometric analysis of tumor vessels
Sections of rat subcutaneous tumors generated in a previous study
[4] were stained with hematoxylin. Representative sections obtained
from three tumors from each group (control and hRAD50-injected)
were analyzed using a Nikon E-600 microscope. Images were captured
with a Spot digital camera, and morphometric analyses were per-
formed using Image-Pro Plus (Media Cybernetics) software. The
whole ¢eld was examined at 200U magni¢cation on each cross-sec-
tion, and the number of vessels per mm2, the total area of tumor
blood vessels, and the sectioned tumor area were determined. The
Student’s unpaired t-test was used to analyze di¡erences in the vessel
number and area.
2.3. Cell cultures
HCAEC and HCASMC were purchased from Clonetics at passage
3 and used until passage 8. These cells were grown in basic media
(EBM2 for EC and SmBM2 for SMC; Clonetics) containing growth
supplements (EGM2MV or SmGM2; Clonetics). HCT116 human co-
lon cancer cells were cultured as described [4].
2.4. Construction of plasmids and transfection
Mammalian expression vector (pFLAG; Eastman Kodak) for
hRAD50 and control CMV-L-gal vector (Clontech) were used as de-
scribed [4]. DNA (2 Wg) was transfected into 70% con£uent cells in
1 ml of culture media with FuGENE 6 following the manufacturer’s
protocol. The transfection rate was measured by counting the stained
cells with L-gal staining solution (Specialty Media). The average trans-
fection rates of the HCAEC, HCASMC, and HCT116 cells were 16%,
24%, and 46%, respectively. In some experiments, 1034 M NG-nitro-L-
arginine-methyl ester (L-NAME; Sigma) was added before transfec-
tion to block the activation of eNOS by hRAD50.
2.5. Fluorescent immunocytochemistry
Cells were seeded for confocal laser scanning microscopy, trans-
fected with vector or hRAD50, washed, ¢xed, probed, visualized
and observed as described [4]. For tubulin staining, monoclonal
mouse anti-alpha tubulin antibody (1:100; Zymed) was used. The
cells were visualized with Alexa Fluor 568-conjugated goat anti-mouse
IgG (Molecular Probes; 1:500) in blocking solution for 30 min. The
nucleus was then counterstained with Sytox Green (1 Wmol, Molecular
Probes) and observed with confocal laser scanning microscopy (Bio-
Rad; 1024).
2.6. NO measurement
Forty-eight hours after the transfection with hRAD50, the media
were collected and stored at 380‡C. After converting nitrate into
nitrite by nitrate reductase, the nitrite contents were measured with
a Colorimetric NO assay kit (Oxford Biomedical Research) following
the manufacturer’s protocol.
2.7. Staining and quantitative measurement of F-actin and G-actin
The cells were ¢xed and permeabilized as described above [5]. If
needed, L-NAME (1034 M) was added before transfection to block
the activation of eNOS by hRAD50. F-actin and G-actin were visu-
alized by staining with Alexa Fluor 488-conjugated phalloidin and
tetramethylrhodamine-conjugated DNase I, respectively, as described
in the manufacturer’s protocol (Molecular Probes). The cells were
observed with confocal laser scanning microscopy.
F-actin and G-actin contents were measured by the methods of
Howard and Oresajo [14]. The F-actin content was obtained from
the absorbance at 518 nm and the G-actin content at 590 nm. The
absorbance of each sample was measured six times for each sample
and averaged. Each experiment was carried out in triplicate and two
independent experiments were performed for each set of samples. To
evaluate the e¡ects of NO on the F/G-actin ratio, the cells were in-
cubated with 50 WM S-nitroso-N-acetylpenicillamine (SNAP; Tocris
Cookson) for 1 day, and the F/G ratio was measured.
2.8. Flow cytometry
hRAD50-transfected HCAEC suspensions with or without
L-NAME (1034 M) pretreatment before transfection were stained
with propidium iodide and Annexin V-FITC (Boehringer Mannheim),
and the status of cell death (two-dimensional FACScan) was mea-
sured with a FACScan £ow cytometer (Becton Dickinson, Sunnyvale,
CA, USA) using a Cycle Test PLUS DNA Reagent kit (Becton
Dickinson).
2.9. In vitro wound-healing assay
The wound-healing assay was performed as described [15]. In brief,
after HCAEC were grown to over-con£uence in a six-well plate, a
scratch was made using a sterile cell-scraper, and a starting point
was marked by attaching a cover glass under the bottom of the plate.
After fresh culture medium was supplied, the vector or hRAD50 was
transfected as described above. The cells were incubated for 2 days,
fresh medium supplied again, and the vector or hRAD50 was trans-
fected again. After the cells were incubated for 2 days longer, cells
that had migrated into the cell-free area were counted under inverted
microscopy (magni¢cationU100). The cells in the ¢ve small grids of
an eyepiece micrometer [Olympus, unit area; 0.1 mm (height)U0.5
mm (width)] just above the starting point were counted and then
the area next to the wound side was counted again. The number of
cells per consecutive unit area were counted, and the process contin-
ued until no cells were observed. The cell counts were plotted using
the consecutive ¢eld number as the abscissa, and both X- and Y-axis
intercepts were calculated by extrapolating the regression line.
2.10. Statistical analysis
Results are expressed as meanRS.E.M. The statistical signi¢cance
of di¡erences between the treatment groups was determined using
ANOVA (analysis of variance) and Student’s unpaired t-test. A value
of P6 0.05 was considered statistically signi¢cant.
3. Results and discussion
3.1. Quanti¢cation of the e¡ects of hRAD50 injection on
tumor-induced angiogenesis in the rat tumor model
Previously, we reported that the subcutaneous tumor had
regressed after 2 weeks following the second injection of
hRAD50, and a complete regression of 14 from 18 established
tumors was achieved within 1 week after the start of regres-
sion [4]. Here, we examined histological sections of tumors
excised from rats injected with vector alone or hRAD50 [4].
The tumors were excised 2 weeks following the second injec-
tion. Microphotographs of hematoxylin-stained sections
showed that proliferating adenocarcinoma cells were abun-
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dant in the vector-injected tumor section (Fig. 1A, inset).
Also, there were many blood vessels in the tumor section
(Fig. 1C). However, in the hRAD50-delivered tumor sections,
tumor margins were well encapsulated (Fig. 1B) and there
were fewer blood vessels (Fig. 1D). Also, there were a lot of
apoptotic cells in the regressed tumor tissue (Fig. 1B, inset).
To achieve a more detailed quanti¢cation of the e¡ects of
hRAD50 injection on tumor-induced angiogenesis, the total
vessel number and vessel area per cross-sectional tumor area
were determined by computer-assisted image analysis of rep-
resentative digital images. Whereas control tumors demon-
strated between 46 and 60 vessels per sectioned tumor area,
the vessel number was signi¢cantly reduced by more than 70%
in hRAD50-injected tumors (Fig. 1E). Also, the total vessel
area was reduced by more than 70% in hRAD50-delivered
tumors as compared with control tumors (Fig. 1F). Likewise,
the relative cross-sectioned tumor area was reduced by more
than 80% in hRAD50-injected tumors (Fig. 1G).
3.2. hRAD50-induced cytoskeletal phenotypes
Since hRAD50 induces the enlargement of the cell and
multinucleation [4], we speculated that the nuclear and cyto-
plasmic morphological changes induced by hRAD50 might be
caused by changes in the cytoskeleton. The subtle changes of
intracellular ¢bers could not be seen easily with regular £uo-
rescent microscopy at low power (data not shown). Instead,
confocal images with a higher magni¢cation was used for
showing the alterations. In control and vector-treated
HCAEC, tubulin was arranged in a radial pattern from the
nucleus to the periphery of the cytoplasm (Fig. 2A,B). How-
Fig. 1. The e¡ect of hRAD50 gene delivery on tumor-induced angiogenesis. The subcutaneous adenocarcinoma tissues of rat given the vector
alone or the hRAD50 expression cassette were analyzed by histology and image analysis. Representative hematoxylin-stained sections (A,B:
low-power ¢eld; C,D: high-power ¢eld) are shown (n=3). Proliferating cells were abundant (inset) in the vector-injected tumor sections (A). In
the hRAD50-delivered tumor sections (B), tumor margins were well encapsulated and there were a lot of apoptotic cells in the regressed tumor
tissue (inset). There were fewer blood vessels (arrows) in the hRAD50-delivered tumor sections (D) than in the vector-injected tumor sections
(C). Quantitative computer-assisted image analysis revealed a signi¢cant inhibition of angiogenesis in the hRAD50 gene delivery group com-
pared with the vector-injected group, as measured by the number of blood vessels (E) and total vessel area (F) per cross-sectional area. The rel-
ative tumor area was reduced seven-fold in the hRAD50 gene delivery group, as compared with the vector-injected group (G). Scale bar A,
1500 Wm; B, 750 Wm; inset, 37.5 Wm; C,D, 75 Wm.
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ever, in the hRAD50-treated HCAEC, the nucleus was bizarre
and divided (Fig. 2C,D). In addition, the arrangement of tu-
bulin was disrupted and distorted (Fig. 2C,D).
In the control and vector-treated groups, F-actin ran from
the edge of one end of the cytoplasm to the opposite side, and
showed a continuous ¢lamentous shape, while the G-actin was
localized near the nucleus (Fig. 2E). However, after hRAD50
transfection, the actin ¢ber arrangement was signi¢cantly
changed. The arrangement of the F-actin was severely dis-
rupted and the amount was reduced (Fig. 2F). Interestingly,
the G-actin was clustered near the nucleus or in the cytoplasm
(Fig. 2G). However, when the cells were pretreated with
L-NAME, the actin arrangement was not disrupted (Fig.
2H). Thus, NO seems to be related to the distorted actin
arrangement in EC transformed with hRAD50.
3.3. Measurement of NO contents in the media and e¡ect of
NO on actin content
We measured NO content in the medium as nitrite after
transient transfection with either vector or hRAD50. NO pro-
duction was signi¢cantly increased in the hRAD50 group
(1.90R 0.55 nmol per 10 000 cells) compared with the vector
group (0.36 R 0.05) at 48 h after transient transfection (Fig.
3A, P6 0.05). The amount of NO produced is equivalent to
4 WM in our study. It is unlikely that the amount of 4 WM is
su⁄cient to induce the apoptosis instead of cell proliferation.
However, due to the paracrine or autocrine nature of released
NO, the total concentration in the medium may not re£ect the
¢ne intracellular NO contents, which is su⁄cient to cause any
signi¢cant changes. Indeed, when the endogenous NO is in-
duced by exogenous stimulant such as humic acid, even
400 pmol per 10 000 cells, an amount of 1/5 of our results,
is su⁄cient to fully induce the apoptosis in human EC [16].
Also, with pretreating with L-NAME, the NO level
(0.42R 0.06) was decreased to the vector-treated level
(0.31R 0.05), indicating that the increased NO contents by
hRAD50 transfection are completely blocked by the treatment
of NOS inhibitor (Fig. 3A).
Previously, we observed that hRAD50 gene transfer in-
creased eNOS expression in the cultured EC and eNOS stain-
ing in the hRAD50-delivered coronary arteries, but iNOS was
not expressed in control or gene-delivered coronary arteries
[5]. However, it was reported that iNOS could be induced in
the EC [17], suggesting the possible involvement of iNOS in
the endothelial homeostasis. Indeed, to address whether the
increased NO release by hRAD50 is derived from eNOS or
iNOS, we have conducted immunoblot with iNOS, but could
not see any changes in iNOS expression (data not shown).
Thus, the increased NO release in the EC by RAD50 seems
to be derived from eNOS activation, however, it does not
mean that iNOS can be completely ruled out in our model.
Since the actin antibody non-speci¢cally binds to F-actin
and G-actin, we adopted, instead of Western blot, a £uores-
cent quanti¢cation of F-actin and G-actin using £uorescent
phalloidin and DNase I, respectively. The F/G-actin ratio was
approximately 2:1 in the vector-transfected HCAEC.
Although the magnitude of changes was small due to transient
transfection, the ratio was signi¢cantly reduced in the
hRAD50-treated group (P6 0.01, Fig. 3B). Interestingly,
treatment with L-NAME blocked the changes in the F/G-actin
ratio in the hRAD50-treated HCAEC (Fig. 3B). However, in
non-endothelial HCT116 cells in which the eNOS expression
is much lower than in the EC, hRAD50 transfection did not
a¡ect the F/G ratio (Fig. 3C), indicating that the hRAD50-
induced change is speci¢c to EC and suggesting that this
change in the F/G ratio is not simply a feature of dying cells.
Fig. 2. hRAD50-induced changes in nuclear shape and micro¢lament arrangement. A^D: Tubulin of HCAEC was visualized. Control (A), vec-
tor-transfected cells (B), and hRAD50-transfected cells (C,D) are shown. Note that hRAD50 disturbs the arrangement of the tubulin (C), and
causes multinucleation (D). E^H: F-actin and G-actin are visualized. Cells transfected with vector (E) or hRAD50 (F,G), or hRAD50 following
L-NAME pretreatment (H) are represented. Note that the hRAD50 induced the disruption of the cell and distortion of F-actin (F). Some typi-
cal G-actin aggregates are shown (G). However, L-NAME prevented the disarray of F- and G-actin by hRAD50 (H). All magni¢cations:
U160.
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To further examine whether NO is ultimately responsible for
the changes in the F/G ratio in HCAEC, we simulated the
e¡ects of transient hRAD50 transfection with the NO donor
SNAP. We used a low concentration of SNAP (50 WM) be-
cause that is su⁄cient to mimic the maximal activation of
eNOS, which is considered to be equivalent to 1^50 WM of
NO donors. SNAP also signi¢cantly reduced the F/G ratio in
the HCAEC (Fig. 3D), indicating that NO mediates the
change in this ratio.
It was reported that gingival epithelial cells exposed to
SNAP exhibited nuclear aberrations, including multilobed nu-
clei and multinucleation [9]. SNAP-induced cell death was
apparently by apoptosis and correlated with the liberation
of NO. Expression of the human eNOS gene in vivo suggests
that NO or its toxic metabolite caused myocardial degrada-
tion, a part of which was compatible with apoptosis of the
transfected cardiomyocytes themselves and the adjacent cells
as a paracrine e¡ect [18]. Also, unique cell degenerations by
overexpression of the eNOS gene were ameliorated by
L-NAME pretreatment. Previously, we observed that
hRAD50 in non-EC resulted in cell death, followed by the
appearance of multinucleated giant cells, and these processes
were p21 dependent [4]. Other studies have also found that
p21 overexpression led to abnormal mitosis and endoredupli-
cation in recovering cells [19,20]. Taken together, these reports
suggest that NO and p21 mediate multinucleation and cyto-
skeletal distortion in EC by hRAD50.
Di¡erent levels of NO may produce di¡erent e¡ects on
cells. NO donors, such as SNAP, S-nitroso-glutathione, sper-
mine NONOate and S-nitrosocaptopril inhibit EC and SMC
proliferation in a concentration-dependent manner [21^23].
Diethylamine NONOate caused concentration-dependent in-
hibition of EC DNA synthesis, which was reversed by the NO
antagonist, cPTIO [22]. SNAP inhibited FGF2-induced neo-
vascularization in the mouse Matrigel implant model [24]. The
level of NO produced by inhibitory concentrations of SNAP
was similar to the NO levels produced by the induction of
iNOS in SMC. Also, NO derived endogenously from iNOS
inhibits proliferation of murine EC lines [25]. However, it was
reported that a low concentration of SNAP inhibited TNFK-
induced endothelial apoptosis partly through the cGMP path-
way, whereas a high SNAP concentration induced endothelial
apoptosis via cGMP-independent pathways [26]. These re-
ports indicate that a low basal level of NO, produced under
physiological conditions, might contribute to human EC sur-
vival through anti-apoptotic e¡ects, whereas a high level of
NO released under pathologic conditions or exogenous gene
transfections might be cytotoxic to EC. Thus, hRAD50 gene
transfer may be useful for the inhibition of neovascularization
associated with cell proliferation due to NO donors.
3.4. NO is involved in necrosis and apoptosis induced by
hRAD50
We investigated the characteristics of cell death in the tran-
sient hRAD50-transfected group by examining a two-dimen-
sional FACScan. hRAD50 transfection increased the fre-
quency of apoptosis (10.05R 0.43% versus 23.31R 3.23%,
P6 0.01) and necrosis (5.36R 0.44% versus 14.92R 2.22%,
P6 0.01) (Fig. 4B) compared with the vector-treated group
(Fig. 4A), indicating that apoptosis and necrosis both contrib-
uted to the death of hRAD50 overexpressing cells.
We also examined the e¡ect of L-NAME on cytotoxicity
with two-dimensional FACScan in order to elucidate whether
NO is related to the necrosis and/or apoptosis induced by
hRAD50 (Fig. 4C,D). When compared with the untreated
group (Fig. 4B), the apoptotic fraction induced by hRAD50
was signi¢cantly reduced from 23.3R 3.2% to 8.6R 0.3% in the
L-NAME-pretreated group (Fig. 4D). However, even when
L-NAME treatment was given, hRAD50 gene transfer still
signi¢cantly increased apoptosis from 5.9R 0.7% to 8.6R
0.3% (Fig. 4D, P6 0.05) when compared with the vector
group (Fig. 4C). Interestingly, in the case of necrosis,
L-NAME blocked the increase in necrosis induced by
hRAD50 (9.30R 0.22% versus 10.05R 1.22%, Fig. 4D). We
represented the cell death in the hRAD50-transfected group
and L-NAME-mediated alteration in cytotoxicity with
changes of the fraction of hRAD50 transfection to that of
vector transfection group (Fig. 4E). It showed that the apo-
ptotic fraction induced by hRAD50 was signi¢cantly dimin-
ished by L-NAME pretreatment (2.32R 0.32% versus 1.46R
0.05%), but L-NAME blocked the increased necrosis induced
by hRAD50 (2.78R 0.41% versus 1.08R 0.13%). Though the
Fig. 3. Measurements of NO and F/G-actin contents. A: The NO contents were measured after forced expression of vector or hRAD50 with
or without L-NAME pretreatment. hRAD50 signi¢cantly increases the amount of NO in the culture media compared with the vector-trans-
fected group. The treatment with L-NAME lowers NO production by hRAD50 approximately to the level of untreated controls. There was sig-
ni¢cant di¡erence in the NO level between the L-NAME-untreated and L-NAME-treated groups. B: The F-actin and G-actin of the transfected
cells were simultaneously stained. In HCAEC, hRAD50 markedly decreased the F/G-actin ratio, while this decrease was completely blocked by
pretreatment with L-NAME. C: hRAD50 failed to alter the F/G-actin ratio in HCT116 cells, non-EC. D: The hRAD50-induced e¡ect on the
F/G-actin ratio was simulated by treatment with SNAP, a NO donor. Asterisks indicate the signi¢cant di¡erences between the hRAD50- and
vector-transfected groups or by L-NAME treatment (*P6 0.05, **P6 0.01; NS, not signi¢cant).
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magnitudes of changes induced by hRAD50 were small due to
transient transfection, these results suggest that NO mediates
both mechanisms of cell death.
3.5. hRAD50 inhibits EC migration in a
wound-healing model
Because hRAD50 induced cytoskeletal di¡erentiated pheno-
types in HCAEC, we used a wound-healing model to test
whether these phenotypes might cause an attenuation of cell
motility and EC migration (Fig. 5A). hRAD50 reduced the
total cell number in the wound area (Fig. 5C, 63.5R 3.4) com-
pared with the vector group (Fig. 5B, 128.0R 12.3, P6 0.01,
n=6), and decreased the X-intercept signi¢cantly (Fig. 5D,
6.3R 0.2 versus 5.5 R 0.2, P6 0.05). Thus, the migrating capa-
bility of hRAD50-transfected cells was reduced. hRAD50 also
decreased the Y-intercept markedly (Fig. 5D, 47.4R 3.6 versus
25.8R 1.3, P6 0.01, n=6), indicating a decreased cell density
at the wound-starting point.
EC migration is an important event in both physiological
and pathological processes of angiogenesis, and is associated
Fig. 5. Wound-healing assay showing the e¡ects of hRAD50 transfection on the proliferation and lateral migration of HCAEC. A: Cells were
scraped out and the wound-starting point was marked with a cover slide as indicated with an arrow. B: Four days after vector transfection,
cells had migrated and proliferated in the cell-free area. EC per unit area were counted using an eyepiece micrometer. C: E¡ects of hRAD50
transfection on EC migration and proliferation. hRAD50 reduced the total EC number in the wound area (C) compared with the vector-treated
group (B). D: Interpretation showing the extent of migration and proliferation of the hRAD50-transfected EC.
Fig. 4. FACScan analysis of hRAD50-transfected HCAEC. Two-dimensional analysis showed that apoptosis (lower right quadrant) and ne-
crosis (upper right quadrant) were augmented in the hRAD50 group (B) compared with the vector group (A). L-NAME pretreatment was given
in the vector- (C) and hRAD50-transfected groups (D). E: The apoptotic and necrotic fractions after hRAD50 transfection were divided by the
mean apoptotic and necrotic fraction values of the vector-treated group, respectively, and expressed with fold changes. The asterisks indicate
the statistical signi¢cances from their vector-treated control groups, while the @ signs show the di¡erences between the L-NAME-treated and
non-treated group (*P6 0.05, **P6 0.01; @P6 0.05, @@P6 0.01; NS, not signi¢cant). The apoptotic fraction induced by hRAD50 was sig-
ni¢cantly diminished by L-NAME pretreatment, but L-NAME blocked the increased necrosis by hRAD50, suggesting that NO mediates both
mechanisms of cell death.
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with regulation of the actin cytoskeleton. SNAP was reported
to inhibit the serum-induced migration of cultured human
umbilical vein EC in a time- and dose-dependent manner.
Sodium nitroprusside also exhibited an antimigratory e¡ect
and superoxide dismutase, a NO protector, enhanced the anti-
migratory e¡ect. Meanwhile, hemoglobin, a NO scavenger,
eliminated the e¡ect. These results indicated that antimigra-
tory e¡ect of SNAP was attributed to NO [27]. Statins, inhib-
itors of 3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase,
block angiogenesis by decreasing EC locomotion. Their e¡ect
is mainly caused by delocalization of RhoA from the cell
membrane to the cytoplasm, thus disorganizing actin stress
¢bers [28]. This antiangiogenic activity could explain the ben-
e¢cial e¡ect of statins on cancer prevention [29]. Our results
indicate that NO donors and hRAD50 inhibit EC migration
through NO-mediated actions, and that statins and hRAD50
inhibit EC migration through disorganization of actin. Thus,
this suggests that hRAD50 inhibits EC migration through
NO-mediated disorganization of actin, and that hRAD50
and statins could be used in localized tumor gene therapy.
Based on our previous in vivo results from hRAD50 gene
injection into tumor tissue and in vitro results showing pro-
found EC death in a static culture system, we previously
tested the e¡ect of local delivery of the hRAD50 gene into
the stent implantation site with a Dispatch catheter [5]. We
hoped to enhance the cytotoxicity in EC by increased produc-
tion of NO through eNOS activation as well as to reduce the
proliferation of EC and SMC through caspase activation. In-
deed, we observed signi¢cant regression of preformed in-stent
neointimal hyperplasia after one-time local delivery of the
hRAD50 gene [5]. Our present results provide in vitro evi-
dence to shed light on the possible underlying mechanisms
for how hRAD50 blocks angiogenesis, and con¢rm the poten-
tial utility of hRAD50 in local gene therapy against prolifer-
ative disorders, such as tumors and coronary restenosis.
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